ASTRAZENECA PHARMA INDIA
|
ASTRAZENECA PHARMA INDIA Last 5 Year Financial Ratios History
[Standalone]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 75.01 | 46.30 | 64.60 | 39.72 | 24.64 |
| CEPS(Rs) | 86.44 | 62.29 | 70.58 | 46.22 | 31.42 |
| DPS(Rs) | 36.00 | 32.00 | 24.00 | 16.00 | 10.00 |
| Book NAV/Share(Rs) | 346.51 | 305.28 | 283.45 | 234.45 | 203.78 |
| Tax Rate(%) | 25.65 | 25.98 | 26.43 | 25.96 | 25.82 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.48 | 14.74 | 14.17 | 16.39 | 10.65 |
| EBIT Margin(%) | 11.25 | 9.16 | 16.95 | 13.37 | 10.38 |
| Pre Tax Margin(%) | 11.05 | 9.08 | 16.86 | 13.31 | 10.26 |
| PAT Margin (%) | 8.22 | 6.72 | 12.40 | 9.85 | 7.61 |
| Cash Profit Margin (%) | 9.47 | 9.04 | 13.55 | 11.47 | 9.70 |
| Performance Ratios | |||||
| ROA(%) | 8.90 | 7.43 | 13.35 | 9.37 | 6.65 |
| ROE(%) | 23.02 | 15.73 | 24.95 | 18.13 | 12.78 |
| ROCE(%) | 31.24 | 21.29 | 33.94 | 24.49 | 17.36 |
| Asset Turnover(x) | 1.08 | 1.11 | 1.08 | 0.95 | 0.87 |
| Sales/Fixed Asset(x) | 11.34 | 8.51 | 7.11 | 5.79 | 4.93 |
| Working Capital/Sales(x) | 3.04 | 2.69 | 2.26 | 2.23 | 2.17 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.09 | 0.12 | 0.14 | 0.17 | 0.20 |
| Receivable days | 31.88 | 35.81 | 36.53 | 35.03 | 38.57 |
| Inventory Days | 126.03 | 82.25 | 58.60 | 59.85 | 67.64 |
| Payable days | 163.79 | 124.39 | 131.27 | 214.92 | 220.48 |
| Valuation Parameters | |||||
| PER(x) | 103.45 | 185.90 | 82.35 | 81.76 | 103.71 |
| PCE(x) | 89.77 | 138.16 | 75.38 | 70.26 | 81.33 |
| Price/Book(x) | 22.39 | 28.19 | 18.77 | 13.85 | 12.54 |
| Yield(%) | 0.46 | 0.37 | 0.45 | 0.49 | 0.39 |
| EV/Net Sales(x) | 8.33 | 12.22 | 9.88 | 7.60 | 7.37 |
| EV/Core EBITDA(x) | 65.23 | 71.21 | 58.36 | 39.84 | 58.85 |
| EV/EBIT(x) | 73.82 | 132.93 | 57.96 | 56.54 | 70.72 |
| EV/CE(x) | 21.71 | 27.23 | 17.97 | 12.94 | 11.62 |
| M Cap / Sales | 8.52 | 12.54 | 10.27 | 8.09 | 7.93 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 32.59 | 32.48 | 29.17 | 24.50 | -0.98 |
| Core EBITDA Growth(%) | -1.38 | 34.37 | 14.66 | 89.44 | -31.94 |
| EBIT Growth(%) | 62.65 | -28.50 | 63.84 | 60.41 | -34.47 |
| PAT Growth(%) | 62.02 | -28.34 | 62.66 | 61.19 | -33.98 |
| EPS Growth(%) | 62.02 | -28.34 | 62.66 | 61.19 | -33.98 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | - | - |
| Current Ratio(x) | 1.68 | 1.70 | 2.23 | 1.93 | 1.95 |
| Quick Ratio(x) | 0.75 | 1.10 | 1.74 | 1.54 | 1.59 |
| Interest Cover(x) | 57.17 | 108.10 | 183.95 | 213.86 | 88.41 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of ASTRAZENECA PHARMA INDIA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| ASTRAZENECA PHARMA INDIA | ₹20,434.8 Cr | -0.1% | -0.6% | -7.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹470,270.0 Cr | -1.5% | 2.5% | 14.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹222,224.0 Cr | 7.4% | 22.2% | 26.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹191,325.0 Cr | 3.1% | 4.3% | 38.5% | Stock Analytics | |
| CIPLA | ₹117,139.0 Cr | -1.6% | -1.4% | -6.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,876.6 Cr | 1.5% | -15.2% | -9.1% | Stock Analytics | |
ASTRAZENECA PHARMA INDIA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ASTRAZENECA PHARMA INDIA | -0.1% |
-0.6% |
-7.3% |
| SENSEX | 2.2% |
0.9% |
-3.7% |
You may also like the below Video Courses
